CTC
EW icon

Central Trust Company’s Edwards Lifesciences EW Stock Holding History

Central Trust Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Sell
2,524
-12
-0.5% -$989 ﹤0.01% 592
2025
Q4 		$216K Buy
2,536
+5
+0.2% +$410 ﹤0.01% 571
2025
Q3 		$197K Sell
2,531
-115
-4% -$8.98K ﹤0.01% 588
2025
Q2 		$207K Hold
2,646
– – ﹤0.01% 564
2025
Q1 		$192K Buy
2,646
+101
+4% +$7.23K ﹤0.01% 570
2024
Q4 		$188K Sell
2,545
-8
-0.3% -$560 ﹤0.01% 569
2024
Q3 		$168K Sell
2,553
-1,355
-35% -$98.4K ﹤0.01% 572
2024
Q2 		$361K Hold
3,908
– – 0.01% 452
2024
Q1 		$373K Buy
3,908
+326
+9% +$27.4K 0.01% 462
2023
Q4 		$273K Sell
3,582
-89
-2% -$6.19K 0.01% 500
2023
Q3 		$254K Buy
3,671
+24
+0.7% +$1.93K 0.01% 510
2023
Q2 		$344K Buy
3,647
+970
+36% +$84.3K 0.01% 470
2023
Q1 		$221K Sell
2,677
-24
-0.9% -$1.89K 0.01% 527
2022
Q4 		$202K Buy
2,701
+1,410
+109% +$109K 0.01% 521
2022
Q3 		$107K Buy
1,291
+40
+3% +$3.85K ﹤0.01% 630
2022
Q2 		$119K Sell
1,251
-607
-33% -$62.8K ﹤0.01% 618
2022
Q1 		$219K Sell
1,858
-8
-0.4% -$897 0.01% 554
2021
Q4 		$242K Buy
1,866
+205
+12% +$23.9K 0.01% 551
2021
Q3 		$188K Buy
1,661
+174
+12% +$19.9K 0.01% 558
2021
Q2 		$154K Buy
1,487
+43
+3% +$4.05K 0.01% 567
2021
Q1 		$121K Hold
1,444
– – ﹤0.01% 573
2020
Q4 		$132K Buy
1,444
+100
+7% +$8.29K 0.01% 543
2020
Q3 		$107K Hold
1,344
– – ﹤0.01% 539
2020
Q2 		$93K Hold
1,344
– – ﹤0.01% 537
2020
Q1 		$85K Hold
1,344
– – 0.01% 534
2019
Q4 		$105K Sell
1,344
-636
-32% -$49.7K 0.01% 554
2019
Q3 		$145K Sell
1,980
-30
-1% -$2.11K 0.01% 488
2019
Q2 		$131K Hold
2,010
– – 0.01% 517
2019
Q1 		$128K Hold
2,010
– – 0.01% 498
2018
Q4 		$103K Hold
2,010
– – 0.01% 527
2018
Q3 		$117K Hold
2,010
– – 0.01% 542
2018
Q2 		$98K Buy
2,010
+102
+5% +$4.76K 0.01% 555
2018
Q1 		$89K Hold
1,908
– – 0.01% 583
2017
Q4 		$72K Buy
1,908
+258
+16% +$9.47K ﹤0.01% 638
2017
Q3 		$60K Hold
1,650
– – ﹤0.01% 649
2017
Q2 		$65K Hold
1,650
– – ﹤0.01% 632
2017
Q1 		$52K Buy
1,650
+90
+6% +$2.82K ﹤0.01% 707
2016
Q4 		$49K Hold
1,560
– – ﹤0.01% 707
2016
Q3 		$63K Hold
1,560
– – ﹤0.01% 610
2016
Q2 		$52K Hold
1,560
– – ﹤0.01% 664
2016
Q1 		$46K Sell
1,560
-10,950
-88% -$302K ﹤0.01% 696
2015
Q4 		$329K Buy
12,510
+900
+8% +$23.4K 0.03% 345
2015
Q3 		$275K Buy
11,610
+11,190
+2,664% +$270K 0.02% 369
2015
Q2 		$10K Hold
420
– – ﹤0.01% 1004
2015
Q1 		$10K Hold
420
– – ﹤0.01% 973
2014
Q4 		$9K Hold
420
– – ﹤0.01% 994
2014
Q3 		$7K Hold
420
– – ﹤0.01% 1028
2014
Q2 		$6K Sell
420
-600
-59% -$8.13K ﹤0.01% 1033
2014
Q1 		$13K Sell
1,020
-1,680
-62% -$19.4K ﹤0.01% 922
2013
Q4 		$30K Buy
2,700
+480
+22% +$5.41K ﹤0.01% 773
2013
Q3 		$26K Hold
2,220
– – ﹤0.01% 788
2013
Q2 		$25K Buy
+2,220
New +$26.3K ﹤0.01% 749

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Central Trust Company's EW Position: Q1 2026 in Review

Central Trust Company reduced its Edwards Lifesciences (EW) stake by 0.47% in Q1 2026, selling an estimated $989 and leaving 2,524 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Central Trust Company first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $373K in Q1 2024. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Central Trust Company held 2,524 shares of Edwards Lifesciences worth $202K as of Q1 2026.
  • Central Trust Company sold 12 Edwards Lifesciences shares in Q1 2026, an estimated $989.
  • Edwards Lifesciences made up ﹤0.01% of Central Trust Company's portfolio in Q1 2026, its #592 holding.
  • Central Trust Company first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Central Trust Company's Edwards Lifesciences position peaked at $373K in Q1 2024.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.